Fluad

ApprovedBiologic

Moderna

Fluad is one of 87 biologic programs targeting Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

InfluenzaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

InfluenzaApproved

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluad

Moderna

Approved

3 2

Fluzone

Sanofi

Preclinical

16 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Avigan

AAppili Therapeutics Inc.

Preclinical

6 5

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 6

COMIRNATY

Pfizer

Preclinical

1 7

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Vaccine Response

NCT05291676

Clinical

Trials by Indication[1]

Vaccine Response3 trials

Systems Investigation of Vaccine Responses in Aging and Frailty

Recruiting·YYale University·Phase 2·NCT05291676·96 enrolled

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Completed·VVanderbilt University Medical Center·Phase 4·NCT04077424·10 enrolled

Effects of Aging on Primary and Secondary Vaccine Responses

Completed·SStanford University·Phase 1·NCT03312699·54 enrolled

Influenza3 trials

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Recruiting·UUniversity of Alabama at Birmingham·Phase 4·NCT04101838·50 enrolled

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Completed·MMcMaster University·Phase 4·NCT02871206·3,425 enrolled

Comparison of 4 Influenza Vaccines in Seniors

Completed·UUniversity of British Columbia·Phase 4·NCT01368796·953 enrolled

Chronic Kidney Disease1 trial

Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis

Completed·KKorea University Guro Hospital·Phase 4·NCT02686398·174 enrolled

Immune Response1 trial

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Completed·UUniversity Hospital, Ghent·Phase 4·NCT02523287·240 enrolled

Gene Expression1 trial

Gene Expression Profiles in Muscle After Immunisation

Completed·UUniversity of Surrey·N/A·NCT02368327·45 enrolled

5 more indications

mRNA Vaccine1 trial

A Study of Modified mRNA Vaccines in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1·NCT05397223·308 enrolled

Immunogenicity1 trial

Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Completed·KKorea University Guro Hospital·Phase 4·NCT02215863·1,195 enrolled

Flu Vaccine1 trial

Training Study to Characterize Biomarkers to Flu Vaccines

Completed·UUniversity of Surrey·N/A·NCT01771367·49 enrolled

Diabetes Mellitus1 trial

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Completed·CChiltern Pesquisa Clinica Ltda·Phase 3·NCT01032395·342 enrolled

Unspecified1 trial

FLUAD® vs. Fluzone® High-Dose Study

Completed·—·Phase 4·NCT03183908·757 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Fluad. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluad compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluad. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Moderna

Fluad

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Vaccine Response3 trials

Influenza3 trials

Chronic Kidney Disease1 trial

Immune Response1 trial

Gene Expression1 trial

mRNA Vaccine1 trial

Immunogenicity1 trial

Flu Vaccine1 trial

Diabetes Mellitus1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News